⚠ A Premium Priced for One Growth Rate Is Mispriced at AnotherModerate threat

Intuitive Surgical (ISRG) — threat to the moat

The utilisation risk premium was set when procedures grew 18%. Guidance is now 13.5% to 15.5%.

Pricing a usage-based lease requires forecasting how many procedures a hospital will perform over several years. That forecast is Intuitive's, and the environment it was made in has changed.

What the usage-based book was underwritten against (%)17%2024 procedures18%2025 procedures14.5%2026 guidance midpoint12%US, Q2 2026467 usage-based systems placed in 2024 and 496 in 2025, into a base now numbering 1,810.
A three-point shortfall is nothing on one system. Compounded over multi-year terms on 1,810 of them, it is the difference between a premium that covers the risk and one that does not.

Systems placed on usage-based terms in 2024 and 2025 — 467 and 496 respectively1 — were underwritten while worldwide da Vinci procedures were growing 17% and 18%2. Full-year 2026 guidance is 13.5% to 15.5%, with management expecting to be nearer the midpoint3, and the United States delivered 12% in the June quarter4.

A three-point shortfall against underwriting is not a crisis on any individual system. Across a base of 1,810 usage-based systems, compounded over multi-year terms, it is the difference between a premium that compensates for risk and one that does not. Intuitive's own warning is that if utilisation differs from expectations there is "no guarantee that we will recuperate the cost of the leased system"5.

The mitigating facts are substantial. The premium is described as modest, so the margin for error was never the source of the return; the systems are placed with established programmes; and gross margin has actually improved, to 67.8% in the June quarter6. Nothing in the reported numbers yet suggests the underwriting is failing.

What would show it is variable lease revenue per usage-based system, roughly $293,000 in 20257. A decline there, while the system count grows, is the arithmetic of an underwriting miss appearing before anybody calls it one.

References
  1. ReportedSystems placed on usage-based terms in 2024 and 2025 — 467 and 496 respectively — were underwritten while worldwide da Vinci procedures were growing 17% and 18%.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedSystems placed on usage-based terms in 2024 and 2025 — 467 and 496 respectively — were underwritten while worldwide da Vinci procedures were growing 17% and 18%.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedFull-year 2026 guidance is 13.5% to 15.5%, with management expecting to be nearer the midpoint, and the United States delivered 12% in the June quarter.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  4. ReportedFull-year 2026 guidance is 13.5% to 15.5%, with management expecting to be nearer the midpoint, and the United States delivered 12% in the June quarter.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  5. ReportedIntuitive's own warning is that if utilisation differs from expectations there is "no guarantee that we will recuperate the cost of the leased system".
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  6. ReportedThe premium is described as modest, so the margin for error was never the source of the return; the systems are placed with established programmes; and gross margin has actually improved, to 67.8% in the June quarter.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  7. Moat Explorer calcThe number that would show it is variable lease revenue per usage-based system, roughly $293,000 in 2025.
    Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
Sources
Generated September 23, 2026